Treatment of Drug Dependence and Psychiatric Illness

描述：(申请人提供) 此K02竞争续期申请的主要目的是进一步 申请人--S在药物依赖治疗领域的科学发展 患者，特别是那些被“双重诊断”为药物滥用和 共存的精神疾病。指导申请者的两个主要假设？S 当前和计划中的研究。第一个是因为药物依赖和双重的 确诊的患者是一个不同的群体，识别有意义的亚组 并针对这些亚群进行针对性的治疗将会有所改善 治疗结果。第二个主要假设是，研究整合 不同的治疗方法(例如，药物治疗和 精神疗法)可以改善药物依赖患者的治疗。这 申请是为了加强申请者？S参与的五项 作为私人助理或联合调查员资助的项目。以下获资助的项目包括 申请人目前正在进行：1)NIDA行为疗法 开发项目，比较两种不同形式的团体治疗 双相情感障碍和物质依赖患者(DA09400，PI)；2)a 多点随机对照试验评价两种药物的组合 药物疗法和行为疗法在酒依赖治疗中的应用 (AA11756，站点PI)；3)研究可卡因遗传学的多站点研究 依赖(DA12849，Site PI)；4)由NIDA资助的一个研究潜力的项目 CDP-胆碱治疗可卡因依赖的疗效(DA11098， 联合调查员)；和5)由NIMH资助的多中心项目，以检查最佳 对双相情感障碍患者的治疗，申请人将 检查共存物质使用障碍患者的治疗方法 (MH80001，药物滥用途径负责人兼联合调查员)。申请人 建议通过学习更多关于遗传学的知识来扩大他的研究能力 和统计方法，通过指导性教程。最后，申请者将 在药物滥用研究生涯中指导年轻的调查人员，并为 作为NIDA治疗研究IRG的审查员，该领域的总体情况 以及参与成瘾问题的国家组织和编辑委员会 日记。

DESCRIPTION: (provided by the applicant) The primary aim of this K02 competing renewal application is to further the applicant?s scientific development in the area of treatment of drug dependent patients, particularly those who are "dually diagnosed" with drug abuse and coexisting psychiatric illness. Two major hypotheses guide the applicant?s current and planned research. The first is that since drug dependent and dually diagnosed patients are a heterogeneous group, identifying meaningful subgroups of patients and targeting specific therapies to these subgroups will improve treatment outcome. The second major hypothesis is that studying the integration of different treatment approaches (e.g., the combination of pharmacotherapy and psychotherapy) can lead to improved treatment for drug dependent patients. This application is designed to strengthen the applicant?s involvement in five funded projects as PI or Co-Investigator. The following funded projects are currently being pursued by the applicant: 1) a NIDA Behavioral Therapies Development Project to compare two different forms of group therapy for patients with bipolar disorder and substance dependence (DA09400, PI); 2) a multi-site randomized controlled trial evaluating combinations of pharmacotherapy and behavioral therapies in the treatment of alcohol dependence (AA11756, Site PI); 3) a multi-site study examining the genetics of cocaine dependence (DA12849, Site PI); 4) a NIDA-funded project examining the potential efficacy of CDP-choline in the treatment of cocaine dependence (DA11098, Co-Investigator); and 5) a multicenter NIMH-funded project to examine optimal treatments for individuals with bipolar disorder, for which the applicant will examine treatments for those patients with coexisting substance use disorder (MH80001, Substance Abuse Pathway Leader and Co-Investigator). The applicant proposes to expand his research capabilities by learning more about genetics and statistical methods through guided tutorials. Finally, the applicant will mentor younger investigators in their drug abuse research careers and serve the field in general through work as a reviewer on the NIDA Treatment Research IRG and participation in national organizations and editorial boards of addiction journals.